Medical Affairs

Investigator-Initiated Studies

The Zevra Therapeutics Investigator-Initiated Studies (IIS) Program will accept unsolicited submissions within our current areas of interest as noted below. Submissions from qualified investigators (i.e., health care professionals, scientists, and researchers) will be reviewed by the Zevra Investigator and Collaborative Research Review Committee for alignment with the AOIs. Research submissions that are not complete, that are not within the scope of these AOIs, or have low relevance to the therapeutic area, may be rejected without further review.

Proposals will be evaluated on their scientific merit to advance science, clinical medicine, and patient care according to availability of resources. Support can include, but is not limited to, drug material, expert advice and/or funding to pay expenses directly related to the research based on fair market value.

The investigator, or the institution the investigator is affiliated with, will serve as the trial sponsor. As such, the sponsor assumes responsibility for initiating and conducting the trial, directing the administration of the trial drug, ensuring compliance with all local laws and regulatory requirements, and analyzing and communicating all trial results.

The goal of the IIS is to advance science and contribute to the development of better medicines for patients consistent with the company’s overall research and development strategies.